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Abstract
Myotonic dystrophy types 1 and 2 (DM1 and DM2) are forms of muscular dystrophy that share similar clinical and molecular
manifestations, such as myotonia, muscle weakness, cardiac anomalies, cataracts, and the presence of defined RNA-
containing foci in muscle nuclei. DM2 is caused by an expansion of the tetranucleotide CCTG repeat within the first intron of
ZNF9, although the mechanism by which the expanded nucleotide repeat causes the debilitating symptoms of DM2 is
unclear. Conflicting studies have led to two models for the mechanisms leading to the problems associated with DM2. First,
a gain-of-function disease model hypothesizes that the repeat expansions in the transcribed RNA do not directly affect ZNF9
function. Instead repeat-containing RNAs are thought to sequester proteins in the nucleus, causing misregulation of normal
cellular processes. In the alternative model, the repeat expansions impair ZNF9 function and lead to a decrease in the level
of translation. Here we examine the normal in vivo function of ZNF9. We report that ZNF9 associates with actively translating
ribosomes and functions as an activator of cap-independent translation of the human ODC mRNA. This activity is mediated
by direct binding of ZNF9 to the internal ribosome entry site sequence (IRES) within the 59UTR of ODC mRNA. ZNF9 can
activate IRES-mediated translation of ODC within primary human myoblasts, and this activity is reduced in myoblasts
derived from a DM2 patient. These data identify ZNF9 as a regulator of cap-independent translation and indicate that ZNF9
activity may contribute mechanistically to the myotonic dystrophy type 2 phenotype.
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Introduction
Myotonic dystrophy types 1 and 2 are forms of muscular
dystrophy resulting from large expansions of nucleotide repeats
within noncoding regions of DMPK and ZNF9, respectively [1].
Myotonic dystrophy type 1 (DM1) is caused by expansion of a
CTG triplet repeat within the 39 untranslated region (UTR) of
DMPK, whereas myotonic dystrophy type 2 (DM2) results from
expansion of a CCTG repeat within the first intron of ZNF9 [2,3].
Despite the different expansions within two apparently unrelated
genes, both diseases share many common clinical manifestations,
including myotonia, muscle weakness, cataract development,
insulin resistance, and cardiac conduction defects. The shared
symptoms suggest the mechanisms causing the disease may also be
shared [4,5]. Although they have similar symptoms, there are also
a number of very dissimilar features making them clearly separate
diseases [6]. A major difference between DM1 and DM2 is that
only DM1 shows a congenital form of the disorder [1]. Other
apparent differences are the distribution of clinical muscle
weakness/atrophy and the morphological involvement of different
fiber types. In DM1, weakness and atrophy involves distal, facial,
bulbar and respiratory muscles, whereas in DM2 the proximal
muscles are preferentially involved, and the patients have marked
muscle pains [7]. DM1 type 1 fibers show atrophy changes
whereas in DM2 a subpopulation of type 2 fibers are highly
atrophic [8]. These phenotypic differences suggest that other
cellular and molecular pathways are involved besides the shared
molecular pathomechanisms.
In both DM1 and DM2, the expanded nucleotide repeats are
transcribed but are not translated. For ZNF9, the transcribed
CCTG repeats within the first intron are apparently removed from
both the wild-type and DM2 pre-mRNAs by splicing, resulting in
translation of the normal ZNF9 protein [9]. Two studies of ZNF9
mRNA and protein expression levels reported no change in diseased
myoblasts or lymphoblastoid cell lines compared to unaffected cells
[9,10]. These results indicate that the repeat RNA does not affect
normal ZNF9 function and have led to a disease model in which the
expanded repeats somehow dominantly interfere with other cellular
processes [11,12,13,14]. This model is supported by the observation
that expression of transgenically engineered expanded CTG repeats
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in unrelated genes can cause some of the phenotypes seen in the
myotonic dystrophies [15]. This toxic-RNA gain-of-function disease
model hypothesizes that the transcribed CTG or CCTG repeat
expansions fold into RNA structures that are retained in the nucleus
forming distinct foci. Experimental data shows the ribonuclear
complexes sequester similar sets of proteins in the nucleus,
apparently causing misregulation of normal cellular processes, in
particular RNA splicing [16,17,18]. Most prominently, the
transcribed CTG and CCTG repeats both bind muscleblind-like
(MBNL) and CUGBP1/ETR-3-like factors (CELF) that are
involved in alternative RNA splicing.
In contrast to the toxic-RNA gain-of-function model, several
studies have revealed a role for ZNF9 in DM2. Knockout of ZNF9
in mice results in embryonic lethality due to defects in forebrain
and craniofacial development [19]. Other studies in chick and
zebrafish show that ZNF9 deletion results in severe brain and
muscle phenotypes [20,21]. Mice heterozygous for the znf9
knockout display late-onset muscle wasting, cardiac abnormalities,
cataracts, and mRNA expression defects similar to those seen in
DM2 [22]. These defects can be rescued by reintroduction of wild-
type levels of ZNF9, suggesting that a loss of ZNF9 function likely
contributes to DM2. Similar to DM2, DMPK deficient mice show
a subset of the phenotypes seen in DM1 patients [23]. A recent
study reports that expanded CCTG repeats in DM2 give rise to
defects in ZNF9 expression and cellular localization [24]. The
discrepancy between this study and earlier characterizations of
ZNF9 expression and localization in DM2 cells is unclear. This
study reported that decreased ZNF9 activity is linked to a
downregulation of translation [24]. A second study has reported
that the expression of the CCTG repeats in mouse and human
myoblasts alters translation and protein degradation [25]. These
data support the notion that the ZNF9 protein may play a role in
DM2 and that the RNA-mediated dominant gain-of-function
model for myotonic dystrophy is not the only pathomechanism for
the disease.
The lack of an in vivo biochemical function for ZNF9 has
hindered the ability to clearly define the role that ZNF9 plays
in DM2. ZNF9 has been proposed to act in a variety of cellular
functions, including transcription, splicing, and translation
[19,26,27,28,29]. Recent evidence suggests that ZNF9 likely acts
as a regulator of translation. ZNF9 associates with 59 terminal
oligopyrimidine (TOP) mRNA elements [30], and 59 TOP
mRNAs are inefficiently translated in DM2 [24]. Previously, our
group identified ZNF9 as a positive regulator of IRES-mediated
translation for the rat ornithine decarboxylase (ODC) mRNA
[26], providing further evidence that ZNF9 functions in
translational regulation.
We hypothesized that ZNF9 acts as an IRES trans-activating
factor (ITAF) for cap-independent translation of the human ODC
mRNA. By analyzing the in vivo function of ZNF9 as an activator
of cap-independent translation, we sought to determine whether a
loss in ZNF9 activity contributes to DM2. The data presented here
suggest that ZNF9 directly interacts with the IRES of the human
ODC mRNA, associates with translating ribosomes, and activates
cap-independent translation. Additionally, our data show that
ZNF9 activity is reduced in myoblasts from a patient affected with
DM2, providing further evidence that a loss-of-function mecha-
nism contributes to myotonic dystrophy type 2 disease.
Materials and Methods
Cell Culture
HEK293T and HeLa cell lines were grown in DMEM
containing 10% fetal bovine serum and penicillin/streptomycin
solution according to standard laboratory practices (ATCC).
Control and DM2 human myoblasts were grown in Complete
Myoblast Medium (Promocell GmbH, Heidelberg, Germany) and
cultured according to the manufacturer’s recommendations. DM2
myoblasts were established from muscle biopsies from a male
patient in his early 40’s with clinical symptoms of DM2. The
(CCTG)n repeat size was approximately 4500 repeats, as
determined using established methods [31].
Plasmid Construction
The full-length 59UTR of the human ODC mRNA from clone
#5088190 (Magic Consortium CloneID) was inserted between the
Renilla and firefly luciferase genes to create pcDNA3.1-hODC-
IRES. pcDNA3.1-V5-ZNF9 was constructed by insertion of the
PCR-generated full-length open reading frame of human ZNF9
into pENTR and subsequent recombination into pcDNA3.1/
nV5-Dest (Invitrogen) by recombinational cloning (Invitrogen).
The PCR primers for cloning ZNF9 were 59- CACCATGAG-
CAGCAATGAGTGCTT-39 and 59- TTATTAGGCTGTAGC-
CTCAATTGTGCA-39. pcDNA3.1-V5-LacZ was created by
recombinational cloning of pcDNA3.1/nV5-GW/lacZ into
pcDNA3.1/nV5-Dest. An HIV –based reporter vector (hODC-
IRES) was cloned by introduction of the full-length hODC-IRES
coding sequence into H163 [32]. pcDNA3.1-hODC-IRES was
digested with KpnI and NotI, blunt-ended with Klenow fragment,
and inserted into the SmaI site of H163. HIV-ZNF9-myc and
HIV-LacZ-Myc were created by digestion of pcDNA3.1-ZNF9-
myc or pcDNA3.1-LacZ-myc with KpnI and PmeI. The fragments
were blunt-ended with Klenow fragment and inserted into the
SmaI site of H163. All clones were verified by DNA sequencing.
Western Blotting
Rabbit polyclonal antibodies were generated against full-length,
recombinant ZNF9 (Covance). Briefly, recombinant human ZNF9
was expressed in E. coli (BL21DE3) as an N-terminal GST fusion
protein and purified by glutathione affinity chromatography.
ZNF9 without the GST tag was released from the column by
cleavage with 3C protease (Prescission Protease, GE). The purity
and identity of ZNF9 were determined by Coomassie staining and
mass spectrometry analysis. ZNF9 antibodies were affinity purified
against full-length recombinant ZNF9. Antibodies for immuno-
blotting were used at the following concentrations: ZNF9
(1:1,000), GAPDH (Millipore) (1:5,000), c-myc (Cell Signaling)
(1:1,000), anti-myc epitope (Vanderbilt Monoclonal Antibody
Core) (1:2,000), V5 (Invitrogen) (1:2,500).
Subcellular Fractionation
HeLa cells were transfected with either pcDNA3.1-ZNF9-myc
or pcDNA3.1-LacZ-myc using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s recommendations. Transfected
cells were fractionated into whole cell, cytoplasmic, and nuclear
fractions using the NE-PER Nuclear and Cytoplasmic Extraction
reagents (Thermo Scientific) according to the manufacturer’s
recommendations.
Quantiative RT-PCR
Total RNA was isolated from cultured cells using TRIzol
according to manufacturer’s recommendations (Invitrogen). RNA
was quantified using a Nanodrop spectrophotometer (Thermo
Scientific). 1 mg of RNA was DNase-treated (Promega) and used in
reverse transcription reactions primed with random hexamers
(Superscript III, Invitrogen). cDNA samples were treated with
RNase H and 5 mL of each sample were used for quantitative real-
ZNF9 Activity in DM2
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time PCR reactions. Real-time PCR was performed using the
Applied Biosystems 7000 and the manufacturer’s protocols
(Applied Biosystems). Taqman probes used were: ZNF9
(Hs00231535_m1) and GAPDH (4333764T).
Sucrose Gradient Analysis and Centrifugation
Polysome analysis was performed as previously described [26].
Intact cells were lysed by repeated vortexing in five pellet
volumes of lysis buffer (100 mM Tris, 10 mM MgCl2, 100 mM
KCl, and 1% TritonX-100), and cellular debris was removed by
centrifugation (4uC, 13,500xg). 10 O.D. units of lysate were
loaded onto a 7–47% sucrose gradient. Unless indicated, sucrose
solutions contained 10 mM Tris-HCl (pH 7.5), 5% cyclohexi-
mide, 5 mM MgCl2, and 100 mM EDTA. Gradients were
centrifuged for 2 h at 178,000xg in a Sorvall SW-41 swinging
bucket rotor. Polysome analysis was performed by bottom
displacement and monitored by UV absorbance at 254 nm.
Fractions were collected for western blotting. Ribosome pelleting
experiments were performed by centrifugation of the cell lysates
described above through a 1 M sucrose cushion (2/+50 mM
EDTA) at 100,000xg for 2 h in a TLA120.2 rotor. The resulting
ribosome pellets were resuspended in ribosome solubilization
buffer (20 mM TRIS pH 7.5, 5 mM MgCl2, 6 M urea).
Supernatant fractions were precipitated with trichloroacetic
acid, washed with acetone, and resuspended in ribosome
solubilization buffer. For ribosome salt wash analysis, ribosome
pellets were isolated as described above, and the supernatants
were discarded. Pellets were washed in ice cold PBS and
resuspended in ribosome salt wash buffer containing 20 mM
Tris-HCl (pH 7.5), 5 mM MgCl2, 1 mM BME, and either
100 mM, 250 mM, 500 mM, or 1 M potassium acetate.
Resuspended ribosomes were then centrifuged at 100,000xg for
2 h in a TLA120.2 rotor. Supernatant fractions were removed
and TCA precipitated as described above, and pellet fractions
were resuspended in solubilization buffer. Equal volumes of
lysate were separated by polyacrylamide gel electrophoresis,
transferred to nitrocellulose membranes, and immunoblotted for
ZNF9 protein.
In Vitro RNA Synthesis and Binding Assays
RNA probes were synthesized using double-stranded DNA
templates with upstream T7 promoters using Ambion’s Mega-
ShortScript kit according to the manufacturer’s recommendations.
The DNA primers used were: 59-TAA TAC GAC TCA CTA
TAG G-39 and 59-GAT TTC TTG ATG TTC CTA TGG AAA
ACT AAG AGA TGG AAT TGA AAG AAA CCT ATA GTG
AGT CGT ATT A-39. The sequence of the synthesized RNA
probe is 59-UUUCUUUCAAUUCCAUCUCUUAGUUUUC-
CAUAGGAACAUCAAGAAAUC-39. The RNA probe was
purified by TRIzol extraction (Invitrogen), and the size and purity
were determined by gel electrophoresis. Probes were end labeled
with 32P using T4 polynucleotide kinase according to the
manufacturer’s recommendations (NEB). All RNA binding
reactions were performed with 20 pmol of labeled RNA in a
reaction volume of 30 mL of RNA binding buffer (150 mM NaCl,
100 mM NaHPO4, and 5% glycerol) in a clear-bottom 96 well
plate at room temperature, unless otherwise indicated. UV cross-
linking reactions were performed on a 302 nm UV lightbox for
5 min at room temperature. Reactions were stopped by addition
of Laemmli buffer. The reactions were analyzed by polyacryl-
amide gel electrophoresis and transferred to nitrocellulose
membranes. Membranes were stained with Ponceau S to measure
ZNF9 protein levels, and exposed to film for imaging of the
radioactive signals.
Luciferase Reporter Assays
HeLa cells were grown in 24-well plates to 70% confluence and
transfected with the human ODC-IRES reporter and either
pcDNA3.1-V5-LacZ or pcDNA3.1-V5-ZNF9 using Lipofecta-
mine 2000 according to manufacturer’s recommendations (Invi-
trogen). Cells were harvested after 24 h, and dual luciferase
reporter assays were performed according to the manufacturer’s
recommendations (Promega) using a Turner TD-20/20 lumnin-
ometer.
Mass Spectrometry-Based Proteomics
Sample preparation and mass spectrometry-based proteomics
analysis were performed as described earlier [26,33].
Generation of shRNA Virus
Double-stranded DNA sequences were generated and cloned
into pENTR/U6 using the Block-iT U6 RNAi Entry vector kit
(Invitrogen). Primer sequences were ZNF9-198 Top strand 59-
CAC CGC AGC AAT GAG TGC TTC AAG TAG AGC TTG
ACT TGA AGC ACT CAT TGC TGC -39, ZNF9-198 Bottom
strand 59-AAA AGC AGC AAT GAG TGC TTC AAG TCA
AGC TCT ACT TGA AGC ACT CAT TGC TGC -39, ZNF9-
645 Top Strand 59-CAC CGC AAG ACA AGT GAA GTC
AAC TAG AGC TTG AGT TGA CTT CAC TTG TCT TGC -
39, ZNF9-645 Bottom Strand 59-AAA AGC AAG ACA AGT
GAA GTC AAC TCA AGC TCT AGT TGA CTT CAC TTG
TCT TGC -39. Ligation products were transformed into One
Shot TOP10 competent E. coli (Invitrogen). Minipreps were
performed on selected colonies and shRNA fidelity was verified
by DNA sequencing. Gateway recombination reactions were
performed by transfering the shRNA constructs into the lentiviral
vector system as described previously [34]. Lentiviruses encoding
ZNF9 or control shRNAs were generated by calcium-phosphate
mediated co-transfection of HEK293T cells with the resul-
ting shRNA-containing lentiviral vector, VSV-G, and pol/gag.
VSV-G and pol/gag vectors were kind gifts of Dr. D. Unutmaz,
NYU School of Medicine [35]. The resulting viral supernatants
were concentrated using Amicon 100K cut-off concentrators
(Millipore).
Viral Infection and Knockdown of ZNF9
Viral supernatants were applied to 16106 HeLa cells cultured
under standard conditions. Infections were performed at an MOI
of 2 and were allowed to proceed for 48 h. GFP+ cells were sorted
and collected using a FACSAria flow sorter (BD Biosciences) and
placed back in culture. Knockdown of target genes was assessed by
quantitative RT-PCR (Taqman) and western blotting directed at
the target protein.
Infection of Primary Myoblasts
HIV-hODC-IRES reporter, HIV-ZNF9-myc, and HIV-LacZ-
myc viral supernatants were generated by calcium phosphate
mediated co-transfection of the HIV vector and pL-VSV-G into
HEK293T cells cultured in DMEM with 10% FBS [32]. The
medium was changed after 6 h and replaced with myoblast
complete growth medium. Supernatants were collected 48 h after
transfection and were sterile filtered and stored at280uC. Primary
myoblasts were seeded at 15,000 cells per well in myoblast
complete growth medium. Viral supernatants were added to the
cells for 8 h, the medium was changed to standard growth
medium, and the cells were subsequently assayed after 48 h for
luciferase activity as described above.
ZNF9 Activity in DM2
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Statistical Methods
Two-tailed Student’s T-tests (95% confidence interval) were
performed on pairwise combinations of data to determine sta-
tistical significance.
Results
ZNF9 Specifically Binds to a Cellular mRNA IRES Element
Previously, we identified ZNF9 in a screen for proteins binding
to an IRES element from the rat ornithine decarboxylase (ODC)
mRNA [26,36]. It was unknown whether ZNF9 directly binds the
ODC’s IRES RNA sequence or if it binds in the presence of other
protein cofactors. We tested whether ZNF9 can bind directly to a
45 bp region in the human ODC mRNA corresponding to the rat
IRES-containing sequence. In Figure 1A, we show that ZNF9
directly binds to the 45 bp human ODC IRES RNA sequence.
The interaction is sequence specific since the interaction was
abolished with the addition of a 50-fold molar excess of an
unlabeled competitor identical to the probe (Fig. 1B). In contrast,
the addition of a 50-fold molar excess of a non-specific competitor
RNA did not reduce or eliminate ZNF9 binding to the ODC
IRES RNA probe (Fig. 1B). The ability of ZNF9 to bind to a
putative IRES element in the absence of other proteins suggests
that it may act as an ITAF through direct recognition of the IRES
sequence. One possible mechanism for ITAF function involves
ZNF9 acting as a physical scaffold between an IRES-containing
mRNA and the ribosomal machinery. Tethering of the mRNA to
the ribosome by an ITAF is thought to facilitate translation of the
mRNA [37,38,39]. In order to test this model for ZNF9, we
investigated the interactions of ZNF9 with the translation
machinery.
ZNF9 Interacts with the Translating Eukaryotic Ribosome
Based on its proposed role as an ITAF for cap-independent
translation, we hypothesized that ZNF9 interacts with translating
ribosomes. Previous work from our lab showed that ZNF9 co-
sediments with the polyribosome fractions, suggesting an interac-
tion with the ribosome and a role in translation [26]. Therefore,
we sought to analyze the intracellular localization of ZNF9 and
whether ZNF9 associates with the ribosome during active
translation. Subcellular fractionation experiments revealed that
the majority of ZNF9 protein is found in the cytoplasm (Fig. 2A).
Both myc-tagged and endogenous ZNF9 localize to the cytoplasm
(Fig. 2A). Western blotting for a known nuclear protein (c-myc)
and a cytoplasmic protein (b-galactosidase) were used as controls
for the selectivity of the fractionation technique. Both control
proteins were found exclusively in the expected fraction. A small
amount (,5%) of the total ZNF9 found in the cell was localized to
the nucleus. While this may be carryover from the cytoplasmic
fraction, the experimental and control results suggest that a small
fraction of ZNF9 is nuclear. The significance and function of
nuclear ZNF9 are unknown, but ZNF9 has been shown previously
to have a nuclear pool [24,25]. The cytoplasmic localization of
ZNF9 is consistent with its proposed role in translation.
Differential centrifugation of high molecular weight complexes
is a well-established technique for the isolation of polyribosomes
[40]. To determine if ZNF9 copurifies with human polysomes,
lysates from HeLa cells were loaded onto a sucrose cushion and
the polyribosome fraction was isolated. The majority of ZNF9 is
found in the pellet (polyribosome) fraction, which suggests that
ZNF9 associates with translating ribosomes (Fig. 2B). A fraction of
ZNF9 protein remains in the supernatant, suggesting that a
portion of ZNF9 protein is not actively engaged with the ribosome
(Fig. 2B). As a control, GAPDH, a protein that does not interact
with translating ribosomes, is absent from the pellet fraction and is
exclusively localized to the supernatant. The addition of EDTA
disrupts polyribosome formation and is often used as a control to
rule out association with other high molecular weight complexes
that co-sediment with ribosomes [33]. In the presence of EDTA,
ZNF9 is found exclusively in the supernatant fraction (Fig. 2B),
suggesting that the ZNF9 sedimentation in the absence of EDTA
is due to an association with the ribosome and not a separate
protein complex. We also analyzed ZNF9 sedimentation with
ribosomes by linear sucrose gradient ultracentrifugation and
confirmed that ZNF9 associates with very high molecular weight
particles and that this interaction is abolished by the addition of
EDTA (Fig. 2C). As seen previously, a fraction of ZNF9 does not
sediment in the ribosome-containing fractions, suggesting that a
pool of ZNF9 is not actively engaged in translation.
In order to further test our hypothesis that ZNF9 acts as a
translation initiation factor for cap-independent translation, we
sought to test how tightly ZNF9 is associated with ribosomal
proteins. Ribosome salt wash experiments are often used to
separate core ribosomal protein subunits from associated transla-
tion factors [41]. The assay is also used to estimate the relative
strength of protein-ribosome interactions by increasing the salt
concentration [42]. We hypothesized that, like other translation
Figure 1. ZNF9 specifically binds to a human cellular mRNA
IRES element. A. Increasing amounts of recombinant, full-length ZNF9
were incubated with 32P-end-labeled ODC RNA probe and cross-linked.
Reactions were separated by polyacrylamide gel electrophoresis,
transferred to nitrocellulose and exposed to X-ray film. Membranes
were stained for ZNF9 protein using Ponceau S. B. Recombinant ZNF9
was incubated with 32P-end-labeled ODC RNA probe and either a 50-
fold molar excess of bovine liver tRNA or a 50-fold molar excess of
unlabeled ODC RNA competitor (comp) probe. Samples were processed
as in A.
doi:10.1371/journal.pone.0009301.g001
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factors, ZNF9 would be released from the polysomes with
intermediate concentrations of salt. At low concentrations of
potassium acetate, ZNF9 localizes exclusively to the ribosome
pellet (Fig. 2D). At 500 mM potassium acetate, a concentration
that is sufficient to strip most translation factors from ribosomes
[40], ZNF9 is partially dissociated from the ribosome. At 1 M
potassium acetate, ZNF9 protein is completely removed from the
ribosome, suggesting that ZNF9-ribosome interactions are not as
strong as the core ribosomal subunits. In summary, our data
indicate that ZNF9 associates with translating polysomes and that
the strength and mode of the interaction is consistent with those of
other translation factors [33,40].
ZNF9 Activates Cap-Independent Translation of the
Human ODC mRNA
We have determined that ZNF9 binds specifically to the 59UTR
of the human ODC mRNA and interacts with translating
ribosomes. Previous data from our lab revealed that ZNF9 can
activate cap-independent translation of the rat ODC mRNA,
which is similar, but not identical, to the human ODC mRNA.
These data suggest a direct role for ZNF9 in regulating translation
of the ODC mRNA. To test if ZNF9 promotes human ODC
IRES activity, a bicistronic reporter plasmid with the full-length
human ODC 59UTR was used to test the ability of ZNF9
to activate cap-independent translation (Fig. 3A). Overexpres-
sion of ZNF9 in HeLa cells resulted in an ,3-fold increase
(p-value = 0.0031) in translation of the second cistron of the
reporter compared to control experiments with b-galactosidase
overexpression (Fig. 3B). These data, along with a demonstration
of direct ZNF9 binding to the 59UTR of ODC, strongly suggests
that ZNF9 acts as a translation factor for cap-independent
translation of the human ODC mRNA.
In order to validate the role for ZNF9 in cap-independent
translation of the human ODC mRNA, we designed specific short
Figure 2. ZNF9 interacts with the translating human eukaryotic ribosome. A. Western blots of sucrose gradient fractions of HeLa cells
extracts transfected with either ZNF9-myc or LacZ-myc and probed with the indicated antibodies. 10% of each fraction was analyzed by western
blotting. WCL: whole cell extract, C: cytoplasmic, N: nuclear B. ZNF9 and GAPDH western blotting of supernatant and polysome fractions of HeLa cell
lysates isolated in the absence or presence of EDTA. Quantification was normalized to the levels of ZNF9 in the supernatant fraction in the absence of
EDTA C. ZNF9 western blotting of sucrose gradient fractions of HeLa cell lysates in the absence or presence of EDTA. Equal cell lysate amounts (10
O.D. units) were applied to each gradient (2/+50 mM EDTA), and each fraction was TCA precipitated. 50% of the total precipitated protein was
analyzed by western blotting. D. ZNF9 western blotting analysis of supernatant and pellet fractions from ribosome salt wash experiments. Western
blots were quantified and the data are reported as ratios of ZNF9 in the pellet fraction to the amount of ZNF9 in the supernatant, normalized to the
values for 100 mM potassium acetate.
doi:10.1371/journal.pone.0009301.g002
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hairpin RNA constructs (shRNAs) to knockdown expression of
ZNF9 mRNA. The short hairpin constructs were expressed in a
lentiviral system for infection into HeLa cells, and infected cells
were selected for stable GFP expression by flow cytometry. Cells
expressing the ZNF9-specific shRNA showed ,90% reductions
(p-value = 2.261025) in ZNF9 mRNA levels and a reduction in
ZNF9 protein levels compared to control shRNA-expressing cells,
as assessed by quantitative RT-PCR and western blotting (Fig. 3C
and insert). These cells with dramatically reduced levels of ZNF9
have ,30% reduction (p-value = 0.0014) in cap-independent
translation of ODC (Fig. 3D), suggesting that ZNF9 is required
for full activation of cap-independent translation of the ODC
mRNA.
Cap-Independent Translation of ODC Is Defective in
Human DM2 Myoblasts
Our data show that ZNF9 stimulates the cap-independent
translation of the ODC mRNA. Using a biochemical assay for
ZNF9 function, we sought to address the critical question of
whether the repeat expansions that cause human DM2 also
compromise this function of ZNF9. If ZNF9 activity is reduced in
Figure 3. ZNF9 activates cap independent-translation of the human ODC mRNA. A. Diagram of the ODC bicistronic vector for measuring
cap-independent translation of human ODC. 59meG: 59-methyl-G cap structure. B. HeLa cells expressing the ODC bicistronic vector and either V5-
ZNF9 or V5-LacZ were analyzed for luciferase activity. The level of cap-independent translation is reported as a ratio of cap-independent translation
(firefly) to cap-dependent translation (Renilla). Values are averages of 6 independent experiments. The error bars are the standard error of the mean
(S.E.M). The insert figure is a representative western blot analysis showing the V5-LacZ and V5-ZNF9 levels in the HeLa cells lysates. C. ZNF9 mRNA
and protein levels after RNAi of ZNF9 in HeLa cells. HeLa cells expressing either a control shRNA or a ZNF9-specific shRNA were analyzed using
quantitative RT-PCR and western blotting to quantify expression of ZNF9 RNA and protein, respectively. The RT-PCR values were computed using the
DDCt method and are normalized to the levels of GAPDH mRNA. Error bars represent the standard error. The insert figure is a western blot showing
the ZNF9 proteins levels. Recombinant ZNF9 (rZNF9) was used as a positive control, and equal amounts of protein were loaded in each lane as
assessed by BCA protein assays. D. HeLa cells expressing the ODC bicistronic vector and either a control or ZNF9-specific shRNA were assessed for
luciferase activity. The level of cap-independent translation is reported as a ratio of cap-independent translation (firefly) to cap-dependent translation
(Renilla). Values are the averages of 3 independent experiments and are normalized to the control shRNA. The error bars are the S.E.M.
doi:10.1371/journal.pone.0009301.g003
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DM2, we predicted that translation of the ODC mRNA would be
reduced compared to wild-type myoblasts. A bicistronic reporter
(HIV-hODC) for cap-independent translation of ODC was
introduced into normal and primary human DM2 myoblasts by
viral infection. We found cap-independent activation of ODC
function is reduced in DM2 (Fig. 4A). DM2 myoblasts show a 31%
reduction (p-value = 0.003) in cap-independent translation of the
ODC reporter (Fig. 4A), providing evidence that cap-independent
translation is reduced in DM2. Using quantitative RT-PCR for
ZNF9, we determined that the DM2 myoblasts used in our
analysis have ,50% of the ZNF9 mRNA (p-value = 0.0003) found
in wild-type myoblasts (Fig. 4B), similar to what was observed in an
earlier study [24].
To test if the reduction in cap-independent translation results
from loss of ZNF9 activity, we tested whether overexpression of
ZNF9 would rescue the defect. We overexpressed ZNF9 or b-
galactosidase in wild-type and DM2 myoblasts by infection with
HIV-based virions. Overexpression of ZNF9 in wild-type
myoblasts increased cap-independent translation 59% (p-value
= 0.0016) as seen previously in the HeLa cell lines (Fig. 3B).
Expression of b-galactosidase (LacZ) in WT and DM2 myoblasts
had no discernible effect on cap-independent translation, as
expected from the results shown in Figure 4A. Overexpression of
ZNF9 in DM2 myoblasts results in a 12% increase (p-value
= 0.235) in cap-independent translation of the ODC reporter
compared to DM2 myoblast controls (Fig. 4C). The level of cap-
independent translation in ZNF9-overexpressing DM2 myoblasts
is not restored to the level of wild-type myoblasts (Fig. 4C). The
results show that ZNF9 overexpression increases cap-independent
translation in both wild-type and DM2 myoblasts, but ZNF9
overxpression in DM2 myoblasts is not sufficient to restore cap-
independent translation of the ODC reporter to the level seen in
wild-type myoblasts.
In summary, our experiments indicate that ZNF9 associates
with actively translating polysomes and activates cap-independent
translation of ODC in cultured cell lines. ZNF9 activates cap-
independent translation in primary human myoblasts, and this
activity is reduced in myoblasts from a DM2 patient. Overex-
pression of ZNF9 partially restores cap-independent translation in
human DM2 myoblasts (Fig. 4C), suggesting that the repeat
expansions causing DM2 probably contribute to the reduction of
at least one aspect of ZNF9 function. However, other modes of
regulating gene expression may be involved and cannot be ruled
out.
Discussion
Misregulation of translational control is a common cause of
multiple diseases, including many cancers, fragile X syndrome,
and vanishing white matter disease [43,44,45,46]. Defects in cap-
independent translation have been shown previously to be linked
to diseases such as X-linked dyskeratosis congenita [47], suggesting
that defects specifically in cap-independent translation can result
in human diseases. Previous investigations into ZNF9 activity
showed that reduced ZNF9 protein expression results in
diminished translational activity and leads to symptoms that
mimic those seen in myotonic dystrophy type 2 [22,24,25].
Our results support a model in which ZNF9 acts as an IRES
trans-activating factor (ITAF) for cap-independent translation of
ODC. ZNF9 binds directly to the 59UTR of the ODC mRNA.
ZNF9 is localized mainly to the cytoplasm and physically
associates with actively translating ribosomes. Overexpression
of ZNF9 activates cap-independent translation of a reporter
construct in tissue culture cells. This ITAF activity is reduced in
Figure 4. Cap-independent translation of ODC is defective in
DM2 myoblasts. A. IRES activity in wild-type and DM2 myoblast. Equal
numbers of human wild-type or DM2 myoblasts were infected with
virions expressing the bicistronic ODC reporter vector and were analyzed
for luciferase activity. The level of cap-independent translation is
reported as a ratio of cap-independent translation (firefly) to cap-
dependent translation (Renilla). Values are averages of 6 independent
experiments and are normalized to IRES activity in wild-typemyoblasts. B.
Differences in ZNF9 mRNA expression in wild-type and DM2 myoblasts.
Quantitative real-time PCR was performed on equal amounts of total
mRNA from wild-type and DM2 myoblasts. Values were computed using
the DDCt method and are normalized to levels of GAPDH mRNA. Error
bars represent the S.E.M. C. IRES activity in wild-type and DM2 myoblast
overexpressing ZNF9. Equal numbers of wild-type or DM2 myoblasts
were infected with the bicistronic ODC reporter vector and vectors for
either the overexpression of LacZ or ZNF9. Cell lysates were analyzed for
luciferase activity as described above. Values are reported as a ratio of
cap-independent translation to cap-dependent translation and are
representative of 4 independent experiments. The values are normalized
to the value of IRES activation in wild-type myoblasts overexpressing
LacZ. Error bars represent the S.E.M.
doi:10.1371/journal.pone.0009301.g004
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primary myoblasts from a myotonic dystrophy type 2 patient.
These results are consistent with a model in which ZNF9 activity is
reduced in DM2 patients.
Because ZNF9 interacts with both an mRNA and ribosomes, one
likely mechanism for its ITAF activity is recognizing specific IRES
sequences or structures within the 59UTR of mRNAs and sub-
sequently recruiting other initiation factors and the ribosome for
translation activation [37,38,39]. It is unknown whether ZNF9
directly recruits the translation machinery or whether other factors
are required. Both PCBP2 and La, known ITAFs, have been
previously shown to interact with ZNF9 and similar RNA substrates
[26,28,29,48]. Interestingly, ZNF9 was found to interact with an
assortment of single-strand RNA binding proteins and ribosomal
protein subunits in a large-scale proteomic screen, consistent with
the possibility that ZNF9 acts in concert with other proteins to
activate translation [49]. Further examination of the interactions of
ZNF9 with mRNAs and specific translation proteins will be
important in elucidating the details of ribosome recruitment during
cap-independent translation, currently a poorly understood process.
The two conflicting models for the cause of DM2 symptoms
stem in part from conflicting data regarding the expression of
ZNF9 mRNA and protein. Two separate studies noted no change
in ZNF9 mRNA and protein levels in DM2 myoblasts or lym-
phoblastoid cell lines [9,10]. These results support the prevailing
toxic-RNA gain-of-function disease model in which the repeat
expansions do not reduce ZNF9 activity but rather interfere with
other critical processes. In contrast, Huichalaf et al. used both
western blotting and in situ antibody staining in DM2 myoblasts to
detect a decrease in ZNF9 protein levels that correlated with
decreased translational activity [24]. These results are consistent
with the loss-of-function disease model, in which the repeat
expansions compromise ZNF9 function. The discrepancies may be
due to low sample numbers, the use of unaffected tissue types
(lymphoblastoid), or differences in the cell line’s genetic back-
grounds. A larger and more comprehensive analysis of ZNF9
protein levels in DM2 is warranted to resolve the discrepancies.
Our study of ZNF9 overexpression in DM2 myoblasts suggests
that neither of the two models completely describes the situation in
DM2. First, we find cap-independent translation is reduced but
not eliminated in myoblasts from DM2 patients compared to
myoblasts from healthy controls, a result expected from loss of
ZNF9 function. The residual activity in DM2 myoblasts may stem
from either low levels of ZNF9, partially active ZNF9, or ZNF9-
independent activity. Overexpression of ZNF9 in normal myo-
blasts results in an increase in cap-independent translation. Thus,
it seems reasonable to expect that overexpression of ZNF9 in DM2
myoblasts would restore cap-independent translation to at least
normal levels. Cap-independent translation activity was slightly
increased compared to control DM2 myoblasts and did not restore
wild-type levels. This result suggests that activation of cap-
independent translation by ZNF9 is somehow blocked in DM2
cells, possibly through a dominant-negative action of the expanded
repeat RNA. Cell-free, reconstituted system in which ZNF9 levels
can be carefully controlled will be important for a clearer
understanding of this phenomenon.
Our data presented here and previous observations suggest that
a combination of an RNA-mediated dominant effect and ZNF9
loss-of-function contribute to DM2. Salisbury et al. have shown
that transcribed CCTG repeats are found in both the nucleus and
the cytoplasm of DM2 myoblasts and that the RNA repeats
misregulate translation [24,25]. ZNF9 may be inhibited by the
presence of transcribed CCTG repeats in the cytoplasm, much as
the RNA splicing factor MBNL activity is thought to be inhibited
by the presence of transcribed CTG and CCTG RNA in the
nucleus [17,50,51]. Both proteins contain multiple zinc finger
motifs to mediate binding to specific RNAs and may be inhibited
by similar substrates. In future work, it will be important to
determine whether ZNF9 and other RNA binding proteins are
inhibited by the presence of transcribed CCTG repeats in either
the nucleus or the cytoplasm.
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